All News
Low IBD Risk with Secukinumab
The interleukin-23 (IL-23)/IL-17 axis plays an important role in inflammation and infection. Some of these chronic immune-mediated inflammatory disorders include PsO, PsA, AS, and IBD. Patients with PsO, PsA, and AS have up to a four-fold risk of developing IBD versus the general population.
Read ArticleVertebroplasty and Kyphoplasty Shown to Be Ineffective
There are approximately 750,000 new vertebral compression fractures each year in the United States, with resultant acute and chronic back pain in over one‐third of patients with vertebral fractures (VF). Both percutaneous vertebroplasty or balloon kyphoplasty have been advocated as useful m
Read ArticleMultidisciplinary Recommendations for Rheumatoid Foot Problems
Approximately 90% of patients with rheumatoid arthritis (RA) have foot problems.
Read ArticleImproved Survival with Renal Transplant in SLE
The Annals of Internal Medicine has published a cohort study of lupus nephritis patients with end-stage renal disease showing that renal transplantation is associated with improved survival benefit, and a reduction in death from cardiovascular disease and infection.
Read ArticleRheumNow Podcast – TNFs and the Inflammasome (1.25.19)
Dr Jack Cush reviews the news from the past week at RheumNow.com.
Read ArticleObesity Needs to be Treated in Psoriatic Arthritis
Obese patients with psoriatic arthritis (PsA) who followed a short-term, very low-energy diet showed improvements in multiple aspects of disease activity, a prospective study found.
Read ArticleMajor Challenges for Lupus in 2019
Despite striking improvements in survival among patients with systemic lupus erythematosus (SLE) in recent decades -- from 1-year survival of less than 50% before the introduction of prednisone to 90% today in most specialized treatment centers -- many challenges remain in this perplexing, multis
Read Article2019: the Year of Price Hikes
In 2019 there have been numerous reports of higher drug pricing for many drugs. Yesterday it was reported that the price of insulin drugs have more than doubled from 2012 to 2016.
Read ArticleSmoking Doesn't Influence Rituximab Responses in Rheumatoid Arthritis
Alcohol, smoking and obesity have all been shown to influence the risk and activity of rheumatoid arthritis (RA) and may also influence response to therapy. This study assesssed whether smoking would influence response to rituximab (RTX) in RA.
Read ArticleU.S. Gout Rates Remain Steady, but Substantial
Using data from 5,467 adults in the US in the National Health and Nutrition Examination Survey (NHANES) for the years 2007-2016, researchers found that the prevalence of gout and hyperuricemia has remained at 3.9%, having doubled from the 1960s to the 1990s, corresponding to an estimated 9.2 mill
Read ArticleDoes Methotrexate Work in Giant Cell Arteritis?
There seems to be both hope and uncertainty regarding the use of weekly methotrexate (MTX) in giant cell arteritis (GCA) patients whom need to limit their glucocorticoid use.
Read ArticleFDA Panel Backs Approval of Romosuzumab for Osteoporosis
The US Food and Drug Administration’s advisory committee on Bone, Reproductive and Urologic Drugs voted Wednesday in favor of approving Amgen’s osteoporosis anti-sclerostin drug, romosozumab (Evenity) for use women with postmenopausal osteoporosis.
Read ArticleAnakinra for Acute Crystal-Induced Arthritis
A retrospective analysis of hospitalized patients who also had a gout and pseudogout attack shows that injections of anakinra (interleukin-1 receptor antagonist) were highly effective and safe in nearly three-quarters of patients.
Read ArticleIL-6 Blocker Succeeds in Real-World Vasculitis
Tocilizumab (Actemra) was effective for refractory giant cell arteritis (GCA) in real-world practice, although serious infections occurred relatively frequently, Spanish investigators reported.
Read ArticleDiet and Weight Loss Improves Psoriatic Arthritis
Short-term intervention with the very low energy diet (VLED) in psoriatic arthritis (PsA) with obesity (body mass index BMI ≥ 33 kg/m2) showed that weight loss was associated with significant positive benefits on weight and disease activity in joints, entheses and skin.
Read ArticleOpioids Double Rates of Suicides and Overdoses
An article in the New England Journal of Medicine reports that the rates of suicide and drug overdoses has doubled in the last 17 years, and that opioids are largely to blame.
Read Article2018 Rheumatology Year In Review
This annual appraisal of hallmark moments, news and research articles from 2018 are gleaned from that published in RheumNow during the last year and filtered by other news sources and literature review. The top 10 list herein is rooted in what rheumatologists should know and what will likel
Read ArticleSevere Cutaneous Sarcoid Treated with Tofacitinib
Researchers from Yale have taken a novel approach and shown benefits when using tofacitinib in severe cutaneous sarcoidosis.
Read ArticleBest of 2018: The Safety of Paternal Exposure to DMARDs and Biologics
Pregnancy and drug safety is a complex issue, often with limited information about maternal drug exposure on the offspring. Greater uncertainty exists when considering whether paternal exposure may also influence fetal outcomes.
Read ArticleBest of 2018: Hydroxychloroquine Being Over-Dosed with New Guidelines?
Hydroxychloroquine retinopathy prevention guidelines have revised from ideal body weight-based dosing to actual body weight-based dosing; the question remains whether these have been adopted in clinical practice.
A database of nearly 21,000 new HCQ users from a UK general population database studied HCQ dosing and use between 2007 and 2016. Specifically they examined whether users were subjected to excess HCQ dosing per ophthalmology guidelines (defined by exceeding 6.5 mg/kg of IBW and 5.0 mg/kg of ABW).


